abstract |
Vaccine (A) comprising defective viral particles (VP) obtained, in vivo or ex vivo, from vertebrates infected by a virus, after transfection of genes carried on a plasmovirus (PV), is new. Vaccine (A) comprises defective viral particles (VP) obtained in vivo or ex vivo, from vertebrates infected by a virus, after transfection of genes carried on a plasmovirus (PV). The PV consists of one or more vectors and contains at least the structural genes necessary for reconstitution of a viral particle that carries immunogenic determinants. Independent claims are also included for the following: (1) vectors for use in production of (A); (2) an immunogenic composition, for prophylactic and/or therapeutic treatment of subjects infected by (or at risk of infection by) a virus, that contains at least one vector of (1); (3) preparation of a live vaccine containing VP by transfecting cells, in vivo or ex vivo, with a vector of (1); and (4) targeting an immunogenic composition by inserting into the env gene of a vector of (1) a sequence that encodes a (poly)peptide having specific affinity for a cellular receptor. |